Get started
Author

Jasmine Moustaquim

Intrapatient 16α-[ 18 F]Fluoro-17β-Estradiol PET Heterogeneity as a Prognostic Factor for Endocrine Therapy Response and Survival in Patients with Estrogen Receptor–Positive Metastatic Breast Cancer
2025 · Jasper J.L. van Geel, Jasmine Moustaquim, et al. · Journal of Nuclear Medicine · 11
PDF
Prognostic and predictive value of human equilibrative nucleoside transporter 1 (hENT1) in extrahepatic cholangiocarcinoma: a translational study
2023 · Lenka N. C. Boyd, Lynn E. Nooijen, et al. · Frontiers in Pharmacology · 10
Clinicopathological and molecular characterization of inflammatory breast cancer, the prospective INFLAME registry study
2025 · Jasper J. L. van Geel, Elisabeth M. Jongbloed, et al. · npj Breast Cancer · 4
PDF
Comparative analysis of FES-PET/CT and FDG-PET/CT in patients with ER-positive metastatic invasive lobular breast cancer
2025 · Jasmine Moustaquim, Gabriëlle E. van Wonderen, et al. · European Journal of Cancer · 3
PDF
436P SONImage: Can molecular imaging predict outcome to first-line endocrine treatment ± CDK 4/6 inhibition in advanced ER+ breast cancer?
2026 · J. Moustaquim, J.J. Knip, et al. · ESMO Open
573P The impact of staging with [18F]FDG PET/CT or ceCT plus bone scintigraphy on long-term outcomes in metastatic breast cancer: Numbers matter
2025 · J. Moustaquim, G. Van Wonderen, et al. · Annals of Oncology
Abstract P4-10-01: Testosterone & Tamoxifen (T&T) trial: adding Testosterone to Tamoxifen in male breast cancer patients
2025 · Jasmine Moustaquim, Jasper van Geel, et al. · Clinical Cancer Research
Abstract PS11-03: Comparative analysis of [18F]FES- and [18F]FDG-PET in patients with metastatic ER+ lobular breast cancer
2025 · Jasmine Moustaquim, Gabriëlle E. van Wonderen, et al. · Clinical Cancer Research
Works count: 9
Citation count: 28
H-index: 3
I10-index: 2
Year
Topic
Type